Level Four Advisory Services’s Checkpoint Therapeutics CKPT Stock Holding History

Level Four Advisory Services’s Portfolio CKPT Stock Details CKPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,000	Closed	-$10K	–	687
2022 Q3	$10K	Hold	1,000	–	–	﹤0.01%	542
2022 Q2	$10K	Hold	1,000	–	–	﹤0.01%	551
2022 Q1	$18K	Hold	1,000	–	–	﹤0.01%	638
2021 Q4	$31K	Buy	+1,000	New	+$33.1K	﹤0.01%	638

Other funds holding CKPT

TwinBeech Capital Purchase, New York $965M AUM 0.23% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAM

PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

PAS

Park Avenue Securities New York $16B AUM 26.77% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Level Four Advisory Services's CKPT Position: Q4 2022 in Review

Level Four Advisory Services sold out of Checkpoint Therapeutics (CKPT) in Q4 2022, closing a stake of 1,000 shares — an estimated $10K sold.

Level Four Advisory Services first reported a position in CKPT in Q4 2021 and held it in 4 quarters. The position peaked at $31K in Q4 2021. 40 funds tracked by Wall St. Rank hold CKPT as of Q4 2022.

Level Four Advisory Services reported no remaining Checkpoint Therapeutics position as of Q4 2022 after selling out during the quarter.
Level Four Advisory Services sold 1,000 Checkpoint Therapeutics shares in Q4 2022, an estimated $10K.
Level Four Advisory Services first reported a position in Checkpoint Therapeutics in Q4 2021 and held it in 4 quarters.
Level Four Advisory Services's Checkpoint Therapeutics position peaked at $31K in Q4 2021.
40 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q4 2022.

Based on Level Four Advisory Services's 13F filing for Q4 2022, filed 13 Feb 2023.